Accurate nodal staging at the time of diagnosis of prostate cancer is crucial in determining a treatment plan for the patient.Pelvic lymph node dissection is the most reliable method,but is less than perfect and has increased morbidity.Cross sectional imaging with computed tomography(CT) and magnetic resonance imaging(MRI) are non-invasive tools that rely on morphologic characteristics such as shape and size of the lymph nodes.However,lymph nodes harboring metastatic disease may be normal sized and non-metastatic lymph nodes may be enlarged due to reactive hyperplasia.The optimal strategy for preoperative staging remains a topic of ongoing research.Advanced imaging techniques to assess lymph nodes in the setting of prostate cancer utilizing novel MRI contrast agents as well as positron emission tomography(PET) tracers have been developed and continue to be studied.Magnetic resonance lymphography utilizing ultra-small super paramagnetic iron oxide has shown promising results in detection of metastatic lymph nodes.Combining MRL with diffusion-weighted imaging may also improve accuracy.Considerable efforts are being made to develop effective PET radiotracers that are performed using hybrid-imaging systems that combine PET with CT or MRI.PET tracers that will be reviewed in this article include [~(18)F]fluoro-D-glucose,sodium [~(18)F]fluoride,[~(18)F]choline,[~(11)C]choline,prostate specific membrane antigen binding ligands,[~(11)C]acetate,[~(18)F]fluciclovine,gastrin releasing peptide receptor ligands,and androgen binding receptors.This article will review these advanced imaging modalities and ability to detect prostate cancer metastasis to lymph nodes.While more research isneeded,these novel techniques to image lymph nodes in the setting of prostate cancer show a promising future in improving initial lymph node staging. Accurate nodal staging at the time of diagnosis of prostate cancer is crucial in determining a treatment plan for the patient. Pelvic lymph node dissection is the most reliable method, but is less than perfect and has increased morbidity. Cross sectional imaging with computed tomography ) and magnetic resonance imaging (MRI) are non-invasive tools that rely on morphologic characteristics such as shape and size of the lymph nodes. Despite lymph node harboring metastatic disease may be normal sized and non-metastatic lymph nodes may be due due to reactive hyperplasia. The optimal strategy for preoperative staging remains a topic of ongoing research. Advanced imaging techniques to assess lymph nodes in the setting of prostate cancer utilizing novel MRI contrast agents as well as positron emission tomography (PET) tracers have been developed and continue to be studied. Magnetic resonance lymphography utilizing ultra-small super paramagnetic iron oxide has shown promising results in detectio n of metastatic lymph nodes. Combining MRL with diffusion-weighted imaging may also improve accuracy. Copleablerable efforts are being made to develop effective PET radiotracers that are performed using hybrid-imaging systems that combine PET with CT or MRI. PET tracers that will be reviewed in this article include [~ (18) F] fluoro-D-glucose, sodium [~ (18) F] fluoride, [~ (18) F] choline, ligands, [~ (11) C] acetate, [~ (18) F] fluciclovine, gastrin releasing peptide receptor ligands, and androgen binding receptors. This article will review these advanced imaging modalities and ability to detect prostate cancer metastasis to lymph nodes. While more research isneeded, these novel techniques to image lymph nodes in the setting of prostate cancer show a promising future in improving initial lymph node staging.